Compare Illumina, Inc. (ILMN) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Sony Group Corp — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while Sony Group Corp trades at $21.01 (market cap $125.96B). The key difference: Sony Group Corp is far larger — about 4.5× Illumina, Inc.'s market cap, and Sony Group Corp pays a 0.75% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | SONY | |
|---|---|---|
Market Cap | $27.94B | $125.96B |
Sector | Health | Technology |
52-Week High | $194.33 | $30.26 |
52-Week Low | $91.00 | $19.32 |
Enterprise Value | $29.33B | $122.45B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
Sony trades at $21.02, down 0.47% on the day. The stock shows a bullish technical signal with strong moving average alignment, though oscillators are neutral. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Revenue for 2025 was $12.96 trillion with a net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive with 11 buy ratings and no sell recommendations.
The outlook for Sony is mixed; strong cash flow and a solid balance sheet support growth in entertainment and AI investments, but the shift away from physical media and projected 2026 losses pose risks. Investor sentiment remains cautiously optimistic given the bullish analyst consensus and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
